ApplicationSingapore (Headquartered at JTC MedTech Hub)Founded 2003· One of 411 Application companies tracked by AMPulse
Developer and manufacturer of 3D-printed bioresorbable implants that facilitate natural bone regeneration.
CEO / Founder
Lim Yujing
Team Size
11-50
Stage
Public
Total Funding
$5.25M
Latest Round
Post-IPO
Key Investors
NTUitive; Institutional, high net worth and sophisticated investors (IPO)
Technology & Products
Key Products
3D printed bioresorbable implants for bone and tissue regeneration, patient-specific surgical models, and sterilized cutting jigs.
Technological Advantage
Microarchitecture design that mimics natural bone structure while meeting specific geometrical needs for reconstruction.
Differentiation
Value Proposition
Bioresorbable implants that dissolve over time while promoting natural bone regeneration, reducing post-surgery complications compared to permanent implants.
How They Differentiate
Unique combination of 3D printing technology with bioresorbable materials that promotes natural bone regeneration.
Market & Competition
Target Customers
Hospitals, surgical centers, and healthcare providers performing neurosurgical, orthopedic, and maxillofacial surgeries
Revenue of approximately $1M in 2018 with continued growth through expanded market presence.
Major Milestones
["Over 30,000 successful surgeries performed","First-in-human 3D printed patient-specific implant for mandibular reconstruction","Expansion into multiple international markets","Successful development of new OrthoMag product line"]
Notable Customers
Major hospitals; Surgical centers; Healthcare providers globally
Osteopore develops and manufactures 3D-printed bioresorbable implants that facilitate natural bone regeneration, positioning itself as a regenerative medicine company rather than a traditional orthopedic implant maker. Founded in 2003 and headquartered at Singapore's JTC MedTech Hub, the company uses polymer material extrusion (MEX) to produce implants with a microarchitecture designed to mimic natural bone structure, meeting specific geometrical needs for reconstruction while eventually dissolving in the body.
The company's core product line includes patient-specific implants for neurosurgery, orthopedics, maxillofacial surgery, and dental surgery, as well as sterilized cutting jigs and surgical models. Osteopore's implants are intended to reduce post-surgery complications associated with permanent metal or polymer implants by eliminating the need for removal surgeries and supporting the body's own healing process. Over 30,000 surgeries have been performed using its technology, including a first-in-human patient-specific implant for mandibular reconstruction.
Osteopore targets hospitals, surgical centers, and healthcare providers globally, with partnerships that include Magloy Tech, DKSH, the University of Chile, and the National University of Singapore. The company has raised approximately $5.25 million in funding from NTUitive and other institutional and high-net-worth investors, and went public via an IPO. Competitors include Matrix Meditec Pvt and Bloocell, though Osteopore differentiates through its proprietary combination of 3D printing and bioresorbable polymer formulations.
A key open question is whether the company can scale revenue beyond the roughly $1 million reported in 2018, given the long regulatory pathways and hospital procurement cycles for implantable medical devices. Its expansion into international markets and development of the OrthoMag product line suggest an effort to broaden its addressable market, but adoption will depend on clinical evidence and surgeon preference versus established metal implant alternatives.
Watch Osteopore
Save it to your watch list and return here after authentication.